Preferred Label : Vidofludimus;
NCIt synonyms : 2-(N-(3-Fluoro-3'-methoxy(1,1'-biphenyl)-4-yl)carbamoyl)cyclopent-1-ene-1-carboxylic
acid;
NCIt definition : An orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH), with potential
anti-inflammatory, immunomodulating and anti-viral activities. Upon administration,
vidofludimus specifically targets, binds to and prevents the activation of DHODH.
This prevents the fourth enzymatic step in de novo pyrimidine synthesis, leading to
inhibition of transcriptional elongation, cell cycle arrest, and apoptosis in activated
lymphocytes. DHODH inhibition also leads to metabolic stress in activated lymphocytes
and inhibition of the release of proinflammatory cytokines including interleukin (IL)-17
(IL-17A and IL-17F) and interferon-gamma (IFNg), thereby reducing inflammation. In
addition, DHODH inhibition may lead to host-based anti-viral activity against many
viruses. DHODH, a mitochondrial enzyme that catalyzes the conversion of dihydroorotate
(DHO) to orotate, is a key enzyme in pyrimidine de novo biosynthesis. Metabolically
highly activated and rapidly proliferating lymphocytes and various virus infected
cells require de novo synthesis to meet their needs for pyrimidines.;
UNII : 8Y1PJ3VG81;
InChIKey : XPRDUGXOWVXZLL-UHFFFAOYSA-N;
CAS number : 717824-30-1;
NCI Metathesaurus CUI : CL554077;
Origin ID : C152873;
UMLS CUI : C2974101;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
